If confirmed by future prospective, randomised, controlled studies (such as ALTTO or APHINITY) this RPPA-based gene expression signature could be used to direct the rationale for adjuvant treatment and research in HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.